Advertisement
U.S. markets open in 6 hours 12 minutes
  • S&P Futures

    5,128.00
    -10.25 (-0.20%)
     
  • Dow Futures

    38,957.00
    -65.00 (-0.17%)
     
  • Nasdaq Futures

    18,182.00
    -80.00 (-0.44%)
     
  • Russell 2000 Futures

    2,072.90
    -2.90 (-0.14%)
     
  • Crude Oil

    78.36
    -0.38 (-0.48%)
     
  • Gold

    2,126.00
    -0.30 (-0.01%)
     
  • Silver

    24.14
    +0.14 (+0.60%)
     
  • EUR/USD

    1.0854
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.2190
    0.0000 (0.00%)
     
  • Vix

    13.49
    0.00 (0.00%)
     
  • GBP/USD

    1.2679
    -0.0014 (-0.11%)
     
  • USD/JPY

    150.4100
    -0.0180 (-0.01%)
     
  • Bitcoin USD

    66,586.99
    +1,705.48 (+2.63%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,621.77
    -18.56 (-0.24%)
     
  • Nikkei 225

    40,097.63
    -11.60 (-0.03%)
     

Why Merck Stock Is Trading Higher Today

Merck & Co Inc's (NYSE: MRKQ1 sales reached $14.49 billion, down 9% Y/Y, beating the consensus of $13.79 billion.

Excluding Lagevrio (COVID-19 treatment), sales growth was 11%; excluding Lagevrio and the impact of foreign exchange, growth was 15%.

Pharmaceutical sales decreased by 10% to $12.72 billion, primarily due to lower sales in virology, mainly attributable to Lagevrio, and diabetes, partially offset by growth in oncology, vaccines, and hospital acute care.

Lagevrio Q1 sales declined 88% Y/Y to $392 million. Ketruda sales grew 20% to $5.8 billion. Gardasil/Gardasil 9 sales grew 35% to $2.0 billion.

Adjusted EPS of $1.40 also surpassed the analysts' estimate of $1.32 and declined 35% Y/Y.

View more earnings on MRK

Also Read: Merck Acquires Prometheus Biosciences For $10.8B, Strengthening Its Immunology Pipeline.

Moderna Inc (NASDAQ: MRNA) and Merck's cancer vaccine exhibited positive results against relapse for melanoma patients.

About 79% of high-risk melanoma patients who got the personalized vaccine and Merck's immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone.

2023 Guidance: Merck has raised and narrowed FY23 adjusted EPS guidance to $6.88-$7.00 compared to prior guidance of $6.80-$6.95 and consensus of $6.91.

Merck anticipates FY23 sales Of $57.7-$58.9 billion compared to previously expected $57.2-$58.7 billion and the consensus of $58.28 billion.

Price Action: MRK shares are up 2.29% at $116.03 during the premarket session on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Why Merck Stock Is Trading Higher Today originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement